Form 4: Cidara Therapeutics COO & CLO Shane Ward Reports Sale of Shares to Cover Tax Obligations

Shane Ward, COO & CLO of Cidara Therapeutics, reports selling 1,664 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• On March 11, 2025, Shane Ward, the COO & CLO of Cidara Therapeutics, sold 1,664 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $21.9604, with individual transactions ranging from $21.93 to $22.37.
• Following the transaction, Ward directly owns 14,674 shares of Cidara Therapeutics.
• This number includes 400 shares acquired through the Employee Stock Purchase Plan on May 20, 2024, and November 20, 2024.
• The reported securities have been adjusted to reflect a 1-for-20 reverse stock split that occurred on April 24, 2024.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates that a company executive sold shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by an insider could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale (tax obligations).

Key Dates